Results 251 to 260 of about 125,678 (274)

Therapeutic and biomarker potential of erythropoietin in neurodegenerative diseases: a systematic review. [PDF]

BMC Neurol
Babazadeh M, Sanaie S, Rahnemayan S.
europepmc   +1 more source

Protocol of ASPro-PD: a phase 3 trial of ambroxol to slow progression in genetically stratified Parkinson's disease. [PDF]

J Neurol
Toffoli M, Menozzi E, Cullen M, Chowdhury K, Ahmed S, Freemantle N, Duffen J, Wyse RK, Stott SRW, Matthews H, Dexter D, Ikeji F, Moss J, Watts P, Foltynie T, Kieburtz K, Rascol O, Poewe W, Schapira AHV.   +18 more
europepmc   +1 more source

Insulin Resistance Surrogates and Cognitive Impairment in Parkinson's Disease: A Cross-Sectional Study with Interpretable Machine Learning. [PDF]

Biomedicines
Liang H, Jia Y, Zhang H, Wang D, Yu H, Yan Y, Li J, Chen L, Xue Z.   +8 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Cancer care for people with dementia: Literature overview and recommendations for practice and research

Ca-A Cancer Journal for Clinicians, 2023
Laura Ashley
exaly  

Dementia prevention, intervention, and care: 2020 report of the Lancet Commission

Lancet, The, 2020
Gill Livingston, Jonathan Huntley, Andrew Sommerlad   +2 more
exaly  

Plasma Homocysteine as a Risk Factor for Dementia and Alzheimer's Disease

New England Journal of Medicine, 2002
Sudha S Seshadri, Alexa S Beiser, Jacob Selhub   +2 more
exaly  

Silent Brain Infarcts and the Risk of Dementia and Cognitive Decline

New England Journal of Medicine, 2003
Niels D Prins, Monique M B Breteler
exaly  

Incidence of Dementia over Three Decades in the Framingham Heart Study

New England Journal of Medicine, 2016
Claudia L Satizabal, Alexa S Beiser, Vincent Chouraki   +2 more
exaly  

Leisure Activities and the Risk of Dementia in the Elderly

New England Journal of Medicine, 2003
Joe Verghese, Charles B Hall, Martin Sliwinski   +2 more
exaly